gill-leng-380_x_215-1

NICE promotes Professor Gillian Leng as its new Chief Executive

pharmafile | March 18, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  NHS, NICE, UK, pharma 

NICE, the drug watchdog for the NHS in England and Wales, has announced that it has promoted Professor Gillian Leng to serve as its new Chief Executive.

She is set to replace current Chief Sir Andrew Dillon who will step down on 1 April, ending his tenure at the organisation he has led since 1999.

Professor Leng steps up from her role as Deputy Chief Executive, a position she has held since 2007, though she also holds the title of Director of Health and Social Care. She was selected for her new role by the non-executive members of NICE’s Board.

Sir Dillon remarked: “I am delighted that Gill has been appointed as NICE’s next Chief Executive. She is an outstanding leader and has all the qualities needed to lead the organisation into its third decade. I am entirely confident that NICE will be safe and successful in her hands.”

Advertisement

Professor Leng also commented on her own appointment: “Under Andrew’s leadership NICE has gained a formidable reputation both nationally and internationally as a world leader in guidance development. I am honoured and privileged to have been appointed as its second Chief Executive. I look forward to working with the Institute’s staff and stakeholders as we enter an exciting new chapter of innovative changes to deliver our portfolio of guidance into the hands of frontline staff in an easy and intuitive way.”

Matt Fellows

Related Content

Scots neonatal innovations target hearing loss and earlier care

Scottish healthcare teams are introducing a range of innovations aimed at improving outcomes for newborns, …

Agentis Health Group acquires Clinical Pharmacist Solutions

Agentis Health Group has acquired Clinical Pharmacist Solutions (CPS), strengthening its pharmacy and digital health …

NICE recommends allergy immunotherapy tablets for younger children

NICE has recommended two sublingual immunotherapy tablets for children with moderate to severe allergic rhinitis …

The Gateway to Local Adoption Series

Latest content